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resumo O Cancro da próstata (CaP) é uma das neoplasias mais frequentemente
diagnosticadas e a segunda causa de morte por cancro no mundo nos
homens. Entre outros factores de risco, a obesidade tem sido frequentemente
associada a CaP, embora permaneçam por esclarecer os mecanismos
subjacentes a esta associação. Com o presente trabalho pretendeu-se através
de estudos in vitro, contribuir para a compreensão do impacto do tecido
adiposo branco e suas sub-fracções (adipócitos e fracção vascular estromal),
com origens anatómicas periprostática e viceral, na proliferação, apoptose, e
invasão celular de células de cancro da próstata sensíveis à castração
(LNCaP) e resistentes à castração (PC-3). Com o propósito de obter respostas
directamente através de estudos em humanos, foram efectuadas culturas
primárias de tecido adiposo periprostático e visceral obtido durante cirurgias
urológicas (prostatectomia radical e adenomectomia prostática) (n=16). O
tecido adiposo foi utilizado para realizar culturas primárias organotípicas
(tecido adiposo total fraccionado) e após digestão com colagenase culturas
primárias de adipócitos e de células da fracção vascular estromal do tecido
adiposo. Foram colhidos sobrenadantes e infranadantes destas culturas de
tecido adiposo e utilizados como meios condicionados representativos da
produção de adipocinas. As linhas celulares LNCaP e PC-3 foram estimuladas
com estes meios e avaliados a apoptose, proliferação celular e invasividade
tumoral in vitro.
Este modelo de estudo representa um potencial meio para análise do impacto
do tecido adiposo nas células tumorais, permitindo avaliar as interacções
tecido adiposo-tumor.
Os resultados evidenciam que o tecido adiposo promove a proliferação das
células tumorais, que o tecido adiposo periprostático aumenta a apoptose em
indivíduos obesos e que os SVF suprimem a invasão das PC-3 através de um
efeito directo nas células tumorais.
abstract Prostate cancer (Pca) is one of the most frequent diagnosed neoplasies and
the second cause of cancer-related death in the world, in men. Between others
risk factors, obesity has been associated to Pca although the innerent
mechanisms to this association remain to be clear. With this work, throuhg in
vitro studies, we wish to contribute to the understanding of the impact of white
adipose tissue and its sub-fractions (adipocytes and stromal vascular fraction),
from visceral and periprostatic anatomic regions, in celular proliferation,
apoptosis and invasion of castration sensitivity (LNCaP) and castration
resistant (PC-3) prostate cells. With the purpose of obtaining answers directly
from humam studies, were performed visceral and periprostatic adipose tissue
primary cultures obtained during urologic surgeries (radical prostatectomy and
prostatic adenomectomy) (n=16). Adipose tissue was used to make primary
organotipical cultures (WAT) and after collagenase digestion adipocytes and
SVF primary cultures. Sobrenatants and infranatants of each culture were
collect and used as conditioned medium representing adipokines production.
LNCaP and PC-3 cell lines were stimulated with these mediums and apoptosis,
proliferation and invasion were evaluated, in vitro.
This study model represent a potential form for analyze the impact of adipose
tissue in tumor cells, allowing to evaluate adipose tissue-tumor interactions.
The results show that adipose tissue promotes tumor cells proliferation, that
periprostatic adipose tissue increase apoptosis in obese individuals and that
SVF subfraction suppresses invasion of PC-3 cells through a direct effect in
tumor cells.
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31. Introduction
1.1 General aspects about cancer
It is estimated that 1 of each 3 persons is affected by cancer all over the world. Ten million
new cases are diagnosed each year, and it is predictable that this number will double in the
next 20 years (Pecorino, 2005).
Tumorigenesis is a multistep process that comprises genetic alterations that ultimately lead
to progressive transformation of normal into malignant cells. This transformation requires
modifications in cell physiology to promote the development of tumor cells, which
Hanahan & Weinberg (2000) defined as hallmarks of cancer: self-sufficiency in growth
signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion from programmed
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue
invasion and metastasis.
In invasive carcinomas, compromise of the basement membrane integrity leads to abnormal
epithelial/mesenchymal heterotypic cell crosstalk. Conversely, albeit most studies focused
on cancer cell-mesenchymal cell interactions have neglected adipose tissue-derived cells;
more concern is being devoted to adipose tissue since it is an excellent candidate
influencing tumor behaviour through heterotypic signalling processes and might prove to
be critical for tumor survival, growth and metastasis.
Additional research is needed, to help determine novel mechanisms and elaborate new
targeted therapies for malignancies treatment and chemoprevention.
1.2 Prostate Cancer: clinics, pathology and molecular mechanisms
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies and the second
cause of cancer-related death in men worldwide (Aus et al., 2005). Its incidence and
mortality seem to have a geographic trend (Fig. 1), since Eastern countries have the lowest
incidence of PCa, contrasting with western countries.
4Ethnicity, advanced age and family history are other well established risk factors for this
disease (Hsing & Chokkalingam, 2006). Furthermore, circulating androgen levels, chronic
prostate inflammation and obesity are also risk factors frequently described in the literature
(Anderson et al., 2000; Platz & De Marzo, 2004; Ribeiro et al., 2006).
Prostate cancer is characterized by a long natural history (Nelson et al., 2003). Autopsy
studies demonstrated that 30-40% of 60 years-old men and 60-70% of men with 80 years-
old had prostate microadenocarcinoma, albeit no previous history of PCa was known (Muir
et al., 1991; Whitmore, 1994).
Fig. 1 Geographic distribution of prostate cancer incidence and mortality rates in 2002 (Parkin et al., 2005)
Prostate cancer screening, recommended in men after 45 years of age, include annual
measurement of blood PSA (Prostate Specific Antigen) levels and digital rectal
examination. Two consecutive rises of PSA value over 0.5 ng/mL or one single value ≥ 4
ng/mL are indications for biopsy (Mistry & Cable, 2003). However, although PSA testing
has high sensibility, its specificity is rather low, putting Clinicians under doubts for
biopsying, since increased false-positive rates, overdiagnosis and overtreatment have been
reported as associated with PSA testing (Nash & Melezinek, 2000; Draisma et al., 2009;
Schroder et al., 2009; Welch & Albertsen, 2009).
5The biological behaviour of PCa exhibits a high inter-individual variability, and is
clinically and pathologically characterized through the percent of tumor volume,
histological differentiation and architecture (Gleason grade) and stage of disease (TNM).
Gleason grade is an indicator of aggressiveness and prognosis, evaluating the extension of
glandular differentiation and the tumor growth status in prostatic stroma (Gleason, 1992;
Humphrey, 2004; Harnden et al., 2007; Heidenreich, 2007).
Due to PCa long natural history, early detection in initial stages has good prognosis.
Although initially men diagnosed in initial stages of disease were usually submitted to
surgery (radical prostatectomy) and/or radiotherapy, with curative intent (Long et al., 2005;
Pronzato & Rondini, 2005), increased concern has been devoted to surgery side-effects
(urinary incontinence and sexual impotence) and several cohorts emerged to demonstrate
the potential of PCa expectant management (Bill-Axelson et al., 2008; Shappley et al.,
2009; Tilling et al., 2009; van den Bergh et al., 2009).
Men diagnosed with advanced stage of disease, not eligible for surgery, are submitted to
chemical or surgical castration that consists of androgen blockade (Cabrespine et al., 2004;
Pronzato & Rondini 2005), since androgens are important in PCa development (Loblaw et
al., 2004; Angelucci et al., 2006). Initially, the neoplasia is sensible to androgen castration
(CSPCa). The administration of combined luteinizing hormone releasing hormone agonists
(LHRHa) plus antiandrogens is the standard therapy for advanced stage or progressing PCa
(Cabrespine et al., 2004; Loblaw et al., 2004). This therapy can delay the tumor growth
because it induces apoptosis of tumor hormonal-dependent cells and reduce PSA levels.
Nevertheless, despite the initial sensibility, PCa evolves more or less rapidly into an
irreversible stage denominated castration-resistant (CRPCa). This is a lethal form of PCa,
with a high potential to progression and metastasis (Feldman & Feldman, 2001). Little is
known about the mechanisms underlying this transformation. Besides hypothesis focused in
androgen receptors expression and mutational profile in castration resistant tumors
(Veldscholte et al., 1990; Van der Kwast et al., 1991; Horbisch et al., 1995; Chen et al.,
2004), there is also evidence that alternative pathways activated by growth factors and
cytokines may modulate or supplant the requirement for androgens to stimulate the
androgen receptor (Craft et al., 1999; Culig, 2004), or even growing independently
(Feldman & Feldman, 2001).
61.3 Obesity: conceptualisation and pathophysiology of adipose tissue
Obesity has become the most common nutritional disorder and its prevalence is increasing
rapidly in most parts of the world (World Health Organization, 2000). The World Health
Organization (WHO) defines obesity as “an abnormal or excessive fat accumulation in
adipose tissue, to the extent that health is impaired”. This statement is quite accurate, even
more because it has been associated with incidence and mortality of a number of diseases,
such as hypertension, coronary heart disease, diabetes, obstructive sleep apnoea, cancer and
others (Klein, et al. 2002; Kopelman, 2000; Flegal et al., 2005).
Body Mass Index (BMI) is commonly used in clinical settings for classifying obesity and to
provide information about disease risk. BMI is calculated using the individual’s weight in
kilograms divided by their height in squared meters. For epidemiological purposes, the
classification of obesity begins at BMI ≥ 30 kg/m2 (World Health Organization, 2000)
(table 1)
Table 1 WHO classification of obesity using BMI. Adapted from Calle & Kaaks (2004)
BMI (Kg/m2) WHO classification Description
< 18.5 Underweight Thin
18.5-24.9 Normal weight Healthy, normal or acceptable
25.0-29.9 Grade 1 overweight Overweight
30.0-39.9 Grade 2 overweight Obesity
≥ 40.0 Grade 3 overweight Morbid obesity
However, a BMI of 30 kg/m2 is not always synonym of obesity. It is important to note that
within each category of BMI there can be substantial individual variation in total and
visceral adiposity, and in several related metabolic variables. This is also true within what
is at present considered the ‘normal’ or ‘healthy’ range of BMI (18.5–24.9). Individuals at
opposite ends of the normal range of BMI can experience considerable differences in
adiposity-related risks and health outcomes (Calle & Kaaks, 2004).
Obesity is characterized by the increased accumulation of triglycerides in adipose tissue, in
subcutaneous and intra-abdominal omental depots, but also in fat surrounding organs such
as kidney, epicardium, skeletal muscle and blood vessels (Montani et al., 2004). This is
7mainly attributable to adipocyte’s hypertrophy, although, to less extent, basal turnover
hyperplasia may also occur (Spalding et al., 2008).
White adipose tissue is a heterogeneous tissue containing adipocytes, pre-adipocytes, and a
stromal vascular fraction (SVF) that include mainly macrophages, endothelial and
mesenchymal cells and fibroblasts (Toda et al., 2009).
Adipose tissue was long known as merely an energy storage organ with the function of
triglycerides repository, but emerging data suggest that adipose tissue is a bioactive
endocrine organ that affects energy balance and has an important functional role in
modulating human disease. Adipose tissue produces several cytokines (such as IL-6, TNF-
α, IL-8, ...), hormones (such as adiponectin, leptin, resistin, …) and growth factors (bFGF,
VEGF, ...) that play crucial roles in obesity (Furhbeck et al., 2001) and cell proliferation
(Onuma et al., 2003) among others (Fig. 2). With only few exceptions, circulating levels of
molecules produced in adipose tissue (adipokines) are increased in obesity, and seem to be
correlated with total fat mass (Arita et al., 1999). In the contrary, adiponectin levels are
negatively correlated with BMI and with visceral fat depot (Arita et al., 1999; Cnop et al.,
2003)
Fig. 2: Adipose tissue and secreted molecules (Tilg & Moschen, 2006)
8Adipokines can impact energy balance and production, while playing a relevant role in
obesity’s pathophysiology. As an example, leptin that is widely expressed during obesity
has been found to act as a satiety hormone by interfering with hypothalamic regulatory
systems involved in the control of food intake (Friedman & Halass, 1998). Cumulatively,
obesity is associated with infiltration of macrophages into adipose tissue, which seem to be
responsible for producing inflammatory markers, therefore perpetuating inflammation into
a chronic condition (Fain et al., 2004; Trujillo & Scherer, 2006).
Spalding et al. (2008) demonstrated recently that fat cells are highly regulated in the human
adult, and because adipocytes are considered differentiated cells the apparent increase of
their number must be due to adipogenesis (proliferation/differentiation of pre-adipocytes to
adipocytes). This issue highlights the possibility of a feedback effect from tumors on
adipose tissue through a paracrine loop. Conversely, Hirano et al. (2008) observed a
stimulatory effect of molecules produced by tumor cells in adipogenesis, reflecting a
crosstalk between tumor cells and adipose tissue.
Although obesity is a multifactorial disease, ultimately it results from a failure of
homeostatic mechanisms that regulate body weight (Blaak, 2009). Positive energy balance
develops when energy intake exceeds its expenditure, and excess energy is then stored in
the form of triglycerides, predominantly in adipose tissue. Energy imbalance due to excess
caloric intake is increasing throughout the world, with increased consumption of processed
food and sedentary lifestyles (Ferranti & Mozaffarian, 2008). Therefore, reducing caloric
intake can prevent and decrease adiposity and its associated health consequeces (Thompson
et al., 2007). In cancer, classic mouse model studies pointed out that caloric restriction was
significantly associated with cancer delay and increased lifespan (Weindruch & Waldorf,
1988; Finch, 1990; Hursting et al., 2003). In vivo studies with p53-deficient mice subjected
to caloric restriction programs, demonstrated carcinogenesis suppression (Berrigan et al.,
2002; Patel et al., 2004).
91.4 Obesity and prostate cancer: epidemiology and mechanistic hypothesis
Obesity is a condition that in the last years has become a worldwide public health problem,
being related with a number of diseases including cancer (Friedman 2000; Kopelman
2000). It has been associated with increased risk to develop several cancers, such as breast,
colorectal, endometrial, or kidney cancer (Bianchini et al., 2002; IACR, 2002; Klein, et al.
2002; Petridou et al., 2002; Calle et al., 2003; Harvie et al., 2003; Stephenson & Rose
2003; Rose et al., 2004; Kuriyama, et al. 2005; Cymbaluk et al., 2008)
Prostate cancer is one of the most diagnosed neoplasies in men, being more frequent in the
western countries, mainly in North America, South European countries and United
Kingdom (Vercelli et al., 2000). Asian men have had lower rates of PCa, albeit recent
studies show a rapid increase, during the last two decades, in Asian countries (Schimizu, et
al., 1991; Pu et al.2004).
Epidemiological studies yielded mixed results on the association of obesity and prostate
cancer. While some cohort studies demonstrate an association of obesity with PCa
(Andersson et al., 1997; Veierod et al. 1997; Engeland et al., 2003;), others failed to find
such an association (Nilsen et al., 1999; Schuurman et al., 2000).
Recent studies, suggest that adult obesity is associated with PCa advanced disease and
high-grade disease (Dal Maso et al., 2004; Robinson et al., 2005; Freedland et al., 2009).
Others established the relation between obesity and higher PCa-associated mortality
(Rodriguez et al., 2001) and predisposition for radical prostatectomy in a much younger age
(Amling et al., 2001).
Some authors have been arguing that obesity by itself can cause difficulties for PCa
detection. In fact, transrectal ultrassonography is more difficult in obese men, eventually
resulting in lower capacity for detecting cancer (Buschmeyer & Freedland, 2007). Another
emerging problem resides in the fact that obese men tend to have significantly lower PSA
values (Gray et al., 2004; Baillargeon et al., 2005; Barqawi et al., 2005), thereby,
masquerading higher levels of PSA and indication for biopsy, resulting in more undetected
cases. Others studies suggest that obese men have larger prostates (Dahle et al., 2002;
Freedland et al., 2006), increasing the difficulty of detecting these cancers through biopsy
(Kranse et al., 1999).
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In obesity serum concentrations of several hormones and growth factors, including
estrogens, insulin, IGF-I, and leptin, are increased, all of which have been linked to prostate
cancer (Freedland & Aronson, 2005).
Obesity is correlated with PCa (Fig. 3) through mechanisms that modify the levels of
estrogens, inflammatory cytokines, growth factors, insulin and adipokines (Meier and
Gressner, 2004; Vendrell et al., 2004; Stattin et al., 2000; Hsing, et al., 2001;Stattin et al.,
2001; Chang at al., 2001).
Fig.3:Schematic representation of the potential mechanisms underlying the obesity–carcinogenesis link. Adapted from
Hursting et al. (2008)
In obesity the levels of resistin are increased, leading to insulin resistance and reducing the
production of IGF binding protein (IGFBP)-1 and IGFBP-2 (usually binds to IGF-I). The
reduction in IGFBP-2 increases free IGF-I resulting in cell microenvironment modifications
that contribute to cancer development, through apoptosis inhibition and stimulation of cell
proliferation (McKeown-Eyssen, 1994 and Giovannucci, 1995) (Fig. 4).
11
Fig. 4: Insulin and IGF mechanism scheme. Adapted from Calle & Kaaks (2004)
Several previous studies linked adipokines to cancer. As an example, the hormones leptin
and adiponectin that are respectively positive and nagatively correlated with adiposity
(Lonnqvist et al., 1997; Montague et al., 1997; ), have been proposed to be associated with
PCa (Chang et al., 2001; Bub et al., 2006; Hoda & Popken, 2008; Mistry et al., 2008; Sher
et al., 2008; Arisan et al., 2009; Li et al., 2010), through a direct role in tumor cell
migration and expression of growth factors (Frankenberry et al., 2004; Mistry et al., 2008;
Tang & Lu, 2009). Other studies support a role for IL-6 production, which is upregulated in
obese, in prostate cancer cell migration and invasiveness (Mistry et al., 2007; Finley et al.,
2009).
Adipose tissue hypoxia (ATH) seems to be a necessary additional mechanism in the
development of systemic insulin resistance, regulation of chronic inflammation and
reduction of adiponectin while increasing leptin gene expression, thus contributing to
cancer risk (Trayhurn et al., 2008). Additionally, tumor hypoxia is correlated with high
mortality and the hypoxia inducible factor-1 alpha (HIF-1α) is associated with an increase
in metastatic range (Vaupel & Hoeckel, 1999).
Another candidate mechanism that provides plausible explanation to obesity-prostate
cancer association is the role of variants in genes that predispose to obesity or in
adipokines’ genes for tumor development. Cancer gene maps were derived from a number
of SNPs and microarrays genome-wide association studies in prostate (Eeles et al., 2008;
Thomas et al., 2008; Moore et al., 2009; Wang et al., 2009). Other gene-targeted studies
12
have been published concerning genetic variants in several adipokine’s pathways (Kote-
Jarai et al., 2003; Ribeiro et al., 2004; Tan et al., 2005; Danforth et al., 2008; Kesarwani et
al., 2008; Langsenlehner et al., 2008).
A recent line of research supports the association obesity-cancer through migration of
adipose stromal cells since the adipose tissue to the tumor. In fact, tumor progression
depends on the establishment of a functional neovasculature, which can rely on progenitor
mesenchymal stromal cells. There is increasing evidence that besides bone marrow-derived
progenitor cells, mesenchymal stromal cells may arise from white adipose tissue and
promote tumor growth (Yu et al., 2008; Zhang et al., 2009).
1.5 Functional impact of adipose tissue in tumor development: animal models and in
vitro studies
Obesity is manifested by overgrowth of white adipose tissue, and it has been proposed that
the tissue itself may have a direct effect on cancer progression (Rehman et al., 2003; Vona-
Davis et al., 2007).
In vitro studies can help us understand the relation between obesity and PCa. It was
recently reported that mature adipocytes co-cultured with breast and colon cancer cells can
promote tumor growth (Manabe et al., 2003; Amemori et al., 2007).
The few studies using PCa cells, demonstrated that co-cultured adipocytes with PCa cell
line resulted in cancer cell proliferation (Tokuda et al., 2003). Another study in prostate
cancer, investigated the association of molecules produced by the periprostatic adipose
tissue with pathological features of aggressive PCa, and found that the over-expression of
IL-6 protein (375 times higher expression in local adipose tissue compared with serum
levels) was responsible for the modulator role of periprostatic adipose tissue in PCa
aggressiveness (Finley et al., 2009).
In a recent elegant study, Zhang et al., 2009 evaluated the recruitment of white adipose
tissue derived cells by tumors and the effect of their engraftment on tumor growth. They
observed migration of stromal and vascular progenitor cell (mesenchymal stromal cells) to
13
the tumor (also prostate tumors), with resulting tumoral neoangiogenesis and accelerated
cancer progression. Nevertheless, contradictory results were obtained in other cancer
models, such as pancreatic cancer (Cousin et al., 2009), suggesting a tumor-type specific
effect. In such models human adipose tissue-derived mesenchymal stem cells is being
studied as a promising source of autologous stem cells for personalized cell-based
therapies, including their role as mediators of prodrug-converting enzymes to inhibit tumor
growth (Kucerova et al., 2007; Cavarretta et al., 2009).
In this emerging field of research, we believe many questions remain to be answered: what
is the result of adipose tissue and its subfractions-derived conditioned medium in PCa cells
growth, apoptosis and invasiveness. Additionally, it is necessary to understand the effect of
conditioned medium from different anatomical fat depots, pre-peritoneal and periprostatic,
which is the extra-prostatic ground for tumor cells after invading the organ capsule.
14
OBJECTIVE

17
2. Objective
2.1.General objective
To get mechanistic insight on the association of obesity with prostate cancer through
human adipose tissue primary cultures experiments. The objective is to evaluate the impact
of molecules produced by the adipose tissue and its sub-fractions in prostate tumor cells
(castration-resistant PC-3 cell line and castration sensible LNCaP cell line).
2.2.Specific objectives
1) To study the effect of molecules produced in primary cultures of human adipose tissue
and sub-fractions (conditioned medium assays) in the proliferation of prostate tumor cell
lines (PC-3 and LNCaP);
2) To analyse the effect of molecules produced in primary cultures of human adipose tissue
and sub-fractions (conditioned medium assays) in the apoptosis of prostate tumor cell lines
(PC-3 and LNCaP);
3) To evaluate the stimulatory effect of conditioned medium from human adipose tissue
cultures in tumor cells’ invasiveness;
4) To understand the impact of anatomical fat depot origin in tumor cell proliferation,
apoptosis and invasiveness.
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3. Material and Methods
3.1.Donors of white adipose tissue samples
Human visceral and periprostatic adipose tissues were obtained during the dissection to
reach the prostate in prostate cancer patients elective for radical prostatectomy or prostatic
adenomectomy in IPO-Porto, Military Hospital of Porto, Terço Order and São Francisco
Order. A total of fifty nine men took part in this study after signing informed consent. The
study was approved by the Institute’s Ethics Committee.
During surgery, after anaesthetic induction and initial dissection to reach the prostate,
samples of visceral pre-peritoneal and anterior-lateral periprostatic fat depots (1-10 g each)
were obtained by a urological surgeon and immediately processed within the surgery room.
Only samples from 16 individuals, choosen randomly, where effectively used. This fact
was due to, time and samples limitations. This group of patients (mean age, 63.27.4 years;
mean BMI, 25.53.3 Kg.m-2) included individuals with benign prostate hyperplasia (BPH)
(n=2) and with prostate cancer (PCa) (n=14).
For proliferation, apoptosis and invasion experiments, patients were divided according to
quartiles of BMI. Patients were stratified in three groups: quartile 0-25 corresponds to BMI
< 24 (n=3); quartiles 25-75 corresponding to a BMI 24-28 (n=10); and quartile 75-100
corresponds to a BMI > 28 (n=3).
3.2. White adipose tissue processing and adipose tissue primary cell cultures
The adipose tissue samples were sectioned and cleaned from macroscopic blood and
vessels and rinsed with phosphate buffer saline plus 1% penicillin and streptomycin
(PBS+PS1%). Adipose tissues from visceral and periprostatic depots (1-5g) were kept in
PBS+PS1% solution at 37ºC for further processing within two hour and used for primary
adipose tissue cell culture.
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 Primary cultures of adipose tissue explants
Adipose tissue samples were transported to the lab in PBS+PS1% at 37ºC and
further processed under a laminar flow hood. A portion of whole adipose tissue (~1-2 g)
from each anatomical location (visceral and periprostatic) was placed in a sterile plastic cell
culture Petri dish for further dissection into 1-2 cm pieces. Then, the adipose tissue
fragments were weighted and placed in 6-well plates (2.5 mL medium per well) at a
quantity of 0.3g explant/mL of culture medium DMEM/F12 (Gibco) suplemented with
biotin 16μM, panthotenate 18 μM, ascorbate 100 μM, PS 1%, and minced with scissors into
5-10 mg pieces.
The explants were incubated overnight at 37ºC with 5% CO2 atmosphere. In the next
morning (~16-24 hours) medium was removed with a pipette tip of 1000 L and fresh
medium added to reach the concentration of 0.3 g tissue/mL. The time that fresh medium
was added was referred to as time zero for time-course experiments. At 24 and 48h the
undernatant was collected (1ml each), centrifuged (20000g, 3 min) and stored at -80ºC.
Fig. 5: Visceral (A) and periprostatic (B) adipose tissue, stained with hematoxilin/eosin (400x)
 Separation of whole adipose tissue into adipocytes and stromal fractions
Whole adipose tissue (WAT) pieces (visceral and periprostatic) were weighted
and placed in a 50 mL Falcon tube with collagenase solution (2 mg/mL) (Collagenase A,
Roche Diagnostics). The tissue was minced with scissors and the tube incubated for 60
minutes at 37ºC with agitation (120 rpm).
A B
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 Primary cultures of adipocytes
After collagenase digestion, the solution was pipeted through a 100 m cell
strainer (BD Falcon) for removing undigested tissues, and the enzyme activity stopped by
adding DMEM/F-12 supplemented medium with 10% NCS.
The solution was then centrifuged at 1800 rpm for 10 minutes at room temperature (RT).
Next, the floating adipocyte layer was removed with a Pasteur pipette, placed in a new tube
and ressuspended in DMEM/F-12 supplemented (without NCS), followed by a
centrifugation at 1100 rpm for 5 minutes at RT. The underneath medium was removed with
a Pasteur pipette and the remaining adipocytes pellet was seeded in a 6 well plate with 2
mL/well DMEM/F-12 supplemented medium. For conditioned medium experiments 1 ml
of cell culture medium was removed at 24 and 48 h, centrifuged at 20000g for 3 minutes at
RT and the undernatants stored at -80º C.
 Primary cultures of adipose tissue-derived stromal vascular fraction cells
After removal of adipocytes layer, the supernatant was discarded. The SVF
pellet was then resuspended in DMEM/F-12 supplemented medium with 10% NCS and
filtered through a 40 m cell strainer for removing remaining adipocytes. After centrifuging
at 1500 rpm for 5 minutes, the supernatant was discarded and the pellet resuspendend and
incubated (15 min at RT) in erythrocyte lysis buffer (QIAgen ).
Afterwards the sample was centrifugated at 1500 rpm for 10 minutes at RT and the
supernatant discarded. SVF were ressuspended and seeded in a 6 well plate with 2 mL
DMEM/F-12 supplemented medium with 10% NCS.
Plates used for culturing SVF, were coated with 1 mL of gelatine 0.2% (Gellatine 2%,
Sigma) and then incubated at 37ºC. After SVF cells adhered to the bottom of plates (Fig.6)
and reached confluence (~48 hours), the medium was removed, the cells washed with PBS
and fresh medium added. This time was referred to as time zero for time-course
experiments. Conditioned medium (1 mL) was collected at 24 and 48 hours, centrifuged at
20000g for 3 minutes at RT and the supernatant stored at –80ºC.
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Fig. 6:  In vitro primary culture of SVF (400x)
3.3.Culture of prostate cancer cell lines (LNCaP and PC-3)
Studies were performed in two established and well characterized prostate cancer lines,
representative of different phases of prostate cancer, androgen-dependent or castration-
sensible (LNCaP) and androgen-independent or castration-resistant (PC-3). PC-3 cells were
obtained directly from ECCAC, while LNCaP cells were gently given by Dr Mariana
Freitas from The General Pathology Institute, Faculty of Medicine, University of Coimbra.
The LNCaP cell line was isolated in 1977, from a needle aspiration biopsy of the left
supraclavicular lymph node of a 50-year-old Caucasian male with confirmed diagnosis of
metastatic prostate carcinoma.
Fig. 7: In vitro culture of LNCaP cells (400x)
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The base medium used for this cell line was RPMI 1640 supplemented with L-glutamine
and Hepes (Gibco), 10% FBS (Gibco) and 1% PS (Gibco). Cells were incubated at 37ºC
with 5% CO2. For conditioned medium experiments, cells were seeded in 12 wells plate
(3x105 cells/well) and allowed to grow until 80% confluence. Then the medium was
removed and replaced by RPMI 1640 + PS (1%) without FBS for 24h until the
administration of conditioned medium.
The PC-3 cell line was derived from a 62-year-old Caucasian male and initiated from a
bone metastasis of a grade IV prostatic adenocarcinoma in 1979 (Fig.8). RPMI 1640
supplemented with L-glutamine and Hepes (Gibco), 10% FBS (Gibco) e 1% PS (Gibco)
was used as basal medium. Cells were incubated at 37ºC with 5% CO2. For conditioned
medium experiments, cells were seeded in 12 well plates (1.5 x 105 cells/well) and allowed
to grow until 80% confluence. Then we removed the medium and replaced it by RPMI
1640 + PS (1%) without FBS.
Fig. 8: PC-3 cells culture (200x)
The time and cell concentration for conditioned medium experiments was determined
previously in our lab. Proliferation was assessed through a fluorescent proliferation assay
(Cell Proliferation Assay Kit, Invitrogen), read in a Fluorimeter plate reader.
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3.4. Leptin dosage in WAT Conditioned medium
In order to determine which medium to use in our experiments, leptin levels were measured
by ELISA (BLK) in supernatants of explants collected at 24 and 48h. Samples from
thirteen different subjects were analysed in duplicate.
3.5.Conditioned medium experiments in PCa cell lines
 Proliferation Experiments
Tumor cells were seeded into 96-well plates (5x103 PC-3 cells/well and 10x103
LNCaP cells/well, 0.2 mL medium) and incubated 24 hours (PC-3) and 48 hours (LNCaP)
with RPMI 1640 medium with 10% FBS to allow cell attachment. After removal of
medium, fresh cell medium with variable percentages of adipose tissue-derived conditioned
medium (from periprostatic and visceral fat from 10 normal weight patients, quartiles BMI
2 and 3) were added to the culture (RPMI 1640 medium without FBS plus 50% CM and
without CM). In these experiments conditioned medium from WAT 48hours, adipocytes
24hours and SVFs 48hours, were used. All samples were performed in duplicate.
After 24h of incubation at 37 ºC and 5% CO2, the supernatant was removed and the cells
were washed with PBS to remove the phenol red from the medium and then freezed at -
80ºC for a minimum of 30min. A mixture of CyQuant dye with cell-lysis buffer was added
to the wells and fluorescence measured at 480nm excitation and 520 nm emission. A
standard curve was previously obtained for each cell type and readings were transformed in
cell counts using this curve.
 Apoptosis Experiments
Tumor cells were seeded into 24-well plates (1 x 105 cells/well, 500μl medium)
and incubated 24 hours (PC-3) and 48 hours (LNCaP) with RPMI 1640 medium with 10%
FBS to allow cell attachment. After supernatant removal, fresh medium, with variable
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percentages of visceral and periprostatic WAT 48h, adipocytes 24h conditioned medium
(from three men in quartile BMI 1 and three men within quartile 4), was added to the
culture (RPMI 1640 medium with no FBS plus 50% CM or no CM). Additionally, a pro-
apoptotic agent (sodium selenite, Na2SeO3) (Menter et al., 2000) was added to the medium
at a 5mM concentration. Twenty four hours later, supernatants and cells were removed
from the wells (adherent cells detached with trypsin 0.05%), centrifuged at 2500 rpm for
3min, washed with cold PBS and centrifuged again. This process was done twice to remove
phenol red of the cells.
Cells were then simultaneously stained with annexin-V-FITC (3g/sample) and PI
(1g/mL) (both from BD Pharmingen). Before the samples were incubated in the dark for
15min, a binding buffer solution (1x) was added (from a 10x stock solution with 0.1M
Hepes, pH 7.4; 1.4M NaCl and 25mM CaCl2).
All samples were analyzed in a flow cytometer (BD FACSCanto II, BD Bioscience, San
Jose, CA), and nuclei gated in a forward/side scatter plot (FSC-A vs SSC-A), to capture the
cells of interest. Propidium Iodide flourescence was read at FL-2 and Anexin V conjugated
with FITC at FL-1. Early apoptotic cells are characterized by high annexin binding and low
PI staining, whereas late apoptotic and necrotic cells stain strongly for both annexin and PI
Fig.9: Apoptosis detection with Annexin V and Propidium Iodide (adapted from www.biomol.de)
Controls used were: unstained cells with sodium selenite, unstained cells without sodium
selenite, only Annexin V-FITC, and only Propidium Iodide.
Up to 10.000 cells were detected in each sample and data acquired using BD FACSDiva
V6.1.1 software (BD Biosciences). All experimental data were analyzed using Infinicyt V1-
1.0 software (Cytognos S.L., Salamanca, Spain). To outline the different populations,
quadrants were set by the unstained cells without sodium selenite.
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 Invasion Assay
Prior to the experiment, PC-3 cells were starved for 24h (RPMI 1640 without
FBS) and incubated at 37ºC with 5% CO2. Pre-warmed serum free medium was added to
the interior of the inserts coated with ECMatrix (Cell Invasion Assay, QCM 24-Well,
Millipore), and allowed to rehydrate the ECM layer for 15-30min at RT. After rehydration,
250μl of medium was removed from the insert and tumor cells seeded inside the inserts in
24-well plates (5x104 PC-3 cells/well). Conditioned medium used in these experiments
were from SVFs 48hours, from men within quartile BMI 1 (n=3) and men within quartile
BMI 4 (n=3).
1) conditioned medium inside the insert
Inside the insert 50% or 0% visceral and periprostatic adipose tissue-derived
conditioned medium (with RPMI 1640 medium without FBS). In the lower chamber was
added tumor cells medium with 10% FBS as chemoattractant. The plate was incubated for
24 hours at 37 ºC with 5% CO2.
Afterwards, the medium and the remaining cells from the top side of the insert were
carefully removed, and the inserts were placed into a clean well containing pre-warmed
Cell Detachment Solution and incubated for 30 min at 37 ºC. After the insert was removed,
a mixture of Lysis Buffer and Dye Solution was added to the well containing the detached
cells, and incubated for 15min at RT (Fig. 10). Two-hundred microliters of each condition
were transferred to a 96-well plate and fluorescence read at 480/520 nm.
This experiment was designed to evaluate the influence of the molecules produced by SVFs
directly in tumor cells invasive potential.
Fig. 10: Representation of the invasion assay.
Lysis Buffer/Dye
Insert
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2) conditioned medium in the well (lower chamber)
Inside the insert tumor cells were cultured in cell medium without FBS. In the lower
chamber 50% and 0% conditioned medium from visceral and periprostatic SVFs. The plate
was incubated for 24 hours at 37 ºC with 5% CO2. The subsequent steps of the protocol
were identical to 1). With this experiment we intended to analyse the chemoattractive
potential of the molecules produced by SVFs.
3.6. Statistical Analysis
The results are expressed as mean  standard error (SE). Differences in cell growth,
apoptosis and invasion distributions between CM treated and corresponding untreated
controls were tested using Student’s t tests. Non-parametric variables were analysed by
Mann-Whitney U test. To analyse differences between independent variables such as BMI
quartile, anatomical origin of CM (periprostatic vs. Visceral) and adipose tissue fractions
(WAT, adipocytes and SVF), adequate Student’s t test or ANOVA analysis were
performed. In proliferation experiment for cell quantification: we created a reference cell
number standard curve for converting sample fluorescence values into cell numbers. Linear
regression for PC-3 standard curve was r2=0.946 and for LNACaP standard curve
r2=0.971.
The significance level was set at P≤0.05.
Statistical analysis was carried out using SPSS 17.0.
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4. Results
Measurement of leptin levels
The leptin levels in supernatants from visceral WAT, at 24h and 48h of in vitro culture are
presented in Figure 11. Leptin was significantly higher in supernatants collected at 48hours
(p=0,006).
Fig.11: Leptin levels in visceral WAT conditioned medium (n=13) at 24h and 48h (Independent Student t test)
Experiment 1: Influence of conditioned medium in PC-3 and LNCaP proliferation
PC-3
The impact of CM from periprostatic and visceral WAT, adipocytes and SVF fractions in
PC3 proliferation are described in Table 2. A trend towards increased proliferative potential
of CRPCa cells PC-3 with CM was found for WAT from visceral and periprostatic depots
(p=0,056 and p=0,057, respectively).
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Table 2: PC-3 cells proliferation under the influence of conditioned medium
0% cond. medium 50% cond.
medium
p*
WAT PP 9006±1976,98 11205±2758,81 0,057
Vis 9739±2845,98 12819±3801,47 0,056
Adipocytes PP 9909±3806,32 11307±3481,50 0,403
Vis 10551±2462,04 11955±4980,39 0,439
SVF PP 12102±5479,27 13972±4283,69 0,407
Vis 11619±4293,53 13904±1813,73 0,147
PP – periprostatic depot; Vis – visceral depot; SVF – stromal vascular fraction; WAT – whole adipose tissue explants.
Mean differences between no CM and 50% CM by Independent Students t test. Values represent mean cell count  SE,
from Q2-Q3 normal weight patients (n=10).
PC-3 cell proliferation after stimulation with CM considering the adipose tissue anatomic
region of origin showed that periprostatic and visceral adipose tissue do not influence
differently castration-resistant tumor cell growth (Fig. 12).
Fig. 12: PC-3 proliferation considering adipose tissue anatomic region. In each subfraction the % of cell count difference
between 50% CM and 0% CM was used (CM from 10 patients within Q2-Q3 of BMI). Differences were computed by
independent Student t tests. PP, periprostatic adipose tissue; VI, visceral adipose tissue; WAT, whole adipose tissue
explants; ADIP, adipocytes; SVF, stromal vascular fraction
Furthermore, we aimed to look at the influence of subfractions within each of the two
anatomic fat depots in PC-3 proliferation. We observed lack of significant differences
between WAT, adipocytes and SVF in cell growth (Fig. 13).
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Fig. 13: In PC-3 cells, cell growth associated with the subfractions WAT, adipocytes and SVF were not different in CM
from periprostatic (A) and visceral (B) origin. Factorial ANOVA and post-hoc LSD was used to determine differences in
cell proliferation between subfractions. In each fat depot and subfraction the % of PC-3 cell count difference between
50% CM and 0% CM was used (CM from 10 patients within Q2-Q3 of BMI). WAT, whole adipose tissue explants;
ADIP, adipocytes; SVF, stromal vascular fraction.
LNCaP
When we analyzed the differences in LNCaP cell proliferation between stimulation with
50% CM and no CM, a significant proliferative input seem to be added by influence
visceral SVF CM, compared with no CM (p=0,002) and a trend to significant growth with
periprostatic SVF CM (p=0,056)  (Table 3).
Table 3: Influence of conditioned medium in LNCaP proliferation
0% cond. medium 50% cond.
medium
p*
WAT PP 352906±140525 309406±109576 0,451
Vis 470906±167495 330156±160883 0,071
Adipocytes PP 474656±133968 392406±95468 0,133
Vis 408156±142062 418156±115925 0,865
SVF PP 480906±157398 606406±111520 0,056
Vis 386406±113825 642656±132115 0,002
PP – periprostatic depot; Vis – visceral depot; SVF – stromal vascular fraction; WAT – whole adipose tissue explants.
Mean differences between no CM and 50% CM by Independent Students t test. Values represent mean cell count  SE,
from Q2-Q3 normal weight patients (n=10).
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In the castration-sensible LNCaP cell line proliferation we observed a trend to significant
growth after stimulation with CM of SVF from visceral origin (p=0.059) (Fig. 14).
Fig. 14: LNCaP cell proliferation considering the origin of adipose tissue (PP vs. VIS). In each subfraction the % of cell
count difference between 50% CM and 0% CM was used (CM from 10 patients within Q2-Q3 of BMI). Differences were
computed by independent Student t tests. PP, periprostatic adipose tissue; VI, visceral adipose tissue; WAT, whole
adipose tissue explants; ADIP, adipocytes; SVF, stromal vascular fraction
The influence of CM from adipose tissue subfractions in each of the two anatomic regions
(VIS and PP) in LNCaP cell proliferation is presented in Figure 15. Significant differences
were observed between WAT and SVF (p=0.003) and between adipocytes and SVF
(p=0.043), in cells stimulated with CM from adipose periprostatic tissue. In visceral tissue
we observed significant differences between the stimulation of LNCaP cells with CM
derived from all subfractions (WAT vs. SVF, p=0.003; WAT vs. Adipocytes, p=0.027;
adipocytes vs. SVF, p=0.011).
Fig. 15: Influence of CM from subfrations of PP (A) and VIS (B) in LNCaP cell proliferation. Factorial ANOVA and
post-hoc LSD was used to determine differences in cell proliferation between subfractions. In each fat depot and
subfraction the % of LNCaP cell count difference between 50% CM and 0% CM was used (CM from 10 patients within
Q2-Q3 of BMI). WAT, whole adipose tissue explants; ADIP, adipocytes; SVF, stromal vascular fraction.
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Experiment 2: Influence of conditioned medium in tumor cell apoptosis
The analysis of CM of subfractions (adipocytes and WAT) derived from periprostatic and
visceral adipose tissues in PC-3 and LNCaP cell apoptosis was made through flow
cytometry with concomitant administration of a pro-apoptotic compound (sodium selenite)
to the culture medium.
The percents of tumor cells in early apoptosis or all the apoptotic (early plus late apoptosis),
after stimulation with adipose tissue-derived CM are described in Tables 4 and 5.
The analysis according to subfractions (adipocytes vs. WAT) showed a trend toward more
total apoptosis in WAT compared to adipocytes alone in castration-resistant PC-3 cells
(p=0.092).
Table 4: Percent of variation in early apoptosis and cells in early/late, considering the differences between LNCaP and
PC-3 cells stimulated with CM of WAT and adipocytes from periprostatic origin.
Subfraction % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Adipocytes 82,49±137,07
0,226WAT 1,10±60,76
%All apoptosis Adipocytes 8,35±79,24
0,847WAT 15,19±24,91
PC
-3
%Early apoptosis Adipocytes -8,15±59,21
0,397WAT 25,45±71,45
%All apoptosis Adipocytes 15,32±31,40
0,092WAT 70,46±62,44
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM from adipocytes and SVF of periprostatic
origin. The % of difference in apoptotic cells between 50% and 0% CM was calculated through the following formula:
apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM). Mean differencesSE are from
experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of BMI). Differences were
computed by independent Student t tests. WAT, whole adipose tissue explants. Early apoptosis refers to cells positive for
Annexin-V but negative for IP, while in all apoptosis we consider all cells positive for Annexin-V.
P=0.165
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When we analysed the influence of visceral adipose tissue-derived CM in LNCaP and PC-3
apoptosis phenotype, no significant differences were observed.
Table 5: Percent of variation in early apoptosis and cells in early/late, considering the differences between LNCaP and
PC-3 cells stimulated with CM of WAT and adipocytes from visceral origin.
Subfraction % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Adipocytes 32,18±109,27
0,589WAT 110,01±316,72
%All apoptosis Adipocytes -8,07±32,15
0,201WAT 28,03±54,74
PC
-3
%Early apoptosis Adipocytes 29,20±61,04
0,410WAT 2,62±44,27
%All apoptosis Adipocytes 4,69±25,87
0,139WAT 31,07±30,64
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM from adipocytes and SVF of visceral origin.
The % of difference in apoptotic cells between 50% and 0% CM was calculated through the following formula: apoptotic
cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM). Mean differencesSE are from experiments
with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of BMI). Differences were computed by
independent Student t tests. WAT, whole adipose tissue explants. Early apoptosis refers to cells positive for Annexin-V
but negative for IP, while in all apoptosis we consider all cells positive for Annexin-V.
When we evaluated if the origin of adipose tissue (periprostatic vs. visceral) could
influence apoptosis, after stimulation with conditioned medium from adipocytes (Table 6)
and WAT (Table 7), no significant differences were observed both in LNCaP and PC-3 cell
lines.
P=0.165
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Table 6: Percent of variation in early apoptosis and cells in early/late, considering the differences between PP and VIS in
adipocytes’ CM on LNCaP and PC-3 apoptosis
Adipocytes % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis PP 82,49±137,07
0,499Vis 32,18±109,27
%All apoptosis PP 8,35±79,24
0,653Vis -8,07±32,15
PC
-3
%Early apoptosis PP -8,15±59,22
0,307Vis 29,20±61,04
%All apoptosis PP 15,32±31,40
0,537Vis 4,69±25,87
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of adipocytes from periprostatic and visceral
origin. The % of difference in apoptotic cells between 50% and 0% CM was calculated through the following formula:
apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM). Mean differencesSE are from
experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of BMI). Differences were
computed by independent Student t tests. PP, periprostatic adipose tissue; Vis, visceral adipose tissue; WAT, whole
adipose tissue explants. Early apoptosis refers to cells positive for Annexin-V but negative for IP, while in all apoptosis
we consider all cells positive for Annexin-V.
Table 7: Percent of variation in early apoptosis and cells in early/late, considering the differences between PP and VIS in
WATs’ CM on LNCaP and PC-3 apoptosis
WAT % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis PP 1,10±60,76
0,443Vis 110,01±316,72
%All apoptosis PP 15,19±24,92
0,617Vis 28,03±54,74
PC
-3
%Early apoptosis PP 25,45±71,45
0,524Vis 2,62±44,23
%All apoptosis PP 70,46±62,44
0,206Vis 31,07±30,64
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of WAT from periprostatic and visceral
origin. The % of difference in apoptotic cells between 50% and 0% CM was calculated through the following formula:
apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM). Mean differencesSE are from
experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of BMI). Differences were
computed by independent Student t tests. PP, periprostatic adipose tissue; Vis, visceral adipose tissue; WAT, whole
adipose tissue explants. Early apoptosis refers to cells positive for Annexin-V but negative for IP, while in all apoptosis
we consider all cells positive for Annexin-V.
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The percent of variation in apoptosis of CM 50% from WAT versus no CM, according to
the patient’s obesity profile is described in Tables 8 and 9.
Table 8: Percent of variation in apoptotic tumor cells, considering the differences between obesity profiles of adipose
tissue donors, when stimulated with visceral WAT conditioned medium
Obesity % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Q1 -30,45±42,53
0,380Q4 250,48±435,63
%All apoptosis Q1 4,97±23,89
0,391Q4 51,10±72,97
PC
-3
%Early apoptosis Q1 -21,83±23,34
0,232Q4 27,07±50,61
%All apoptosis Q1 16,58±33,99
0,300Q4 45,55±23,70
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of WAT from visceral origin, according to
the obesity phenotype of patients. The % of difference in apoptotic cells between 50% and 0% CM was calculated through
the following formula: apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM). Mean
differencesSE are from experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of BMI).
Differences were computed by independent Student t tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI; WAT, whole
adipose tissue explants. Early apoptosis refers to cells positive for Annexin-V but negative for IP, while in all apoptosis
we consider all cells positive for Annexin-V.
Lack of influence of the background obesity phenotype of patients was observed when
visceral and periprostatic WAT explants-derived CM was used for testing apoptosis.
We can observe that in LNCaP cells, the conditioned medium of individuals with the
obesity profile Q4 cause increased early apoptosis (p=0,029), demonstrating a pro-
apoptotic effect of periprostatic WAT-derived CM in obese individuals (Table 9).
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Table 9 Percent of variation in apoptotic tumor cells, considering the differences between obesity profiles of
adipose tissue donors, when stimulated with periprostatic WAT conditioned medium
Obesity % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Q1 -48,57±18,85
0,029Q4 50,77±38,37
%All apoptosis Q1 28,37±30,21
0,267Q4 2,02±10,91
PC
-3
%Early apoptosis Q1 -17,59±51,77
0,159Q4 68,48±67,28
%All apoptosis Q1 53,54±61,05
0,569Q4 87,37±71,84
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of WAT from periprostatic origin, according
to the obesity phenotype of patients. The % of difference in apoptotic cells between 50% and 0% CM was calculated
through the following formula: apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM).
Mean differencesSE are from experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of
BMI). Differences were computed by independent Student t tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI; WAT,
whole adipose tissue explants. Early apoptosis refers to cells positive for Annexin-V but negative for IP, while in all
apoptosis we consider all cells positive for Annexin-V.
The percentage of variation in apoptosis after stimulation with visceral adipocyte’s CM,
according to the obesity profile is described in Table 10. Lack of significant differences
between obese and thin individual’s visceral adipocytes-derived CM were found.
Table 10: Percent of variation in apoptotic tumor cells, considering the differences between obesity profiles of adipose
tissue donors, when stimulated with visceral adipocyte’s CM
Obesity % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Q1 -19,88±13,95
0,344Q4 84,24±146,72
%All apoptosis Q1 -21,77±10,95
0,391Q4 5,63±43,61
PC
-3
%Early apoptosis Q1 33,61±83,50
0,883Q4 24,79±47,81
%All apoptosis Q1 5,47±36,29
0,951Q4 3,91±18,83
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of adipocytes from visceral origin, according
to the obesity phenotype of patients. The % of difference in apoptotic cells between 50% and 0% CM was calculated
through the following formula: apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0% CM).
Mean differencesSE are from experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the Q4 of
BMI). Differences were computed by independent Student t tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI. Early
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apoptosis refers to cells positive for Annexin-V but negative for IP, while in all apoptosis we consider all cells positive for
Annexin-V.
We can observe a pro-apoptotic effect of periprostatic adipocytes-derived CM in PC-3 cells
in obese (p=0,022), and a tendency toward a significant pro-apoptotic influence in Q4
individuals (p=0,080) (Table 11).
Table11: Percent of variation in apoptotic tumor cells, considering the differences between obesity profiles of adipose
tissue donors, when stimulated with periprostatic adipocyte’s CM
Obesity % of difference
between 50%-0%CM
p*
LN
Ca
P
%Early apoptosis Q1 -16,16±64,56
0,080Q4 181,13±116,65
%All apoptosis Q1 -5,99±38,18
0,719Q4 22,70±116,72
PC
-3
%Early apoptosis Q1 -51,14±12,85
0,108Q4 34,84±55,29
%All apoptosis Q1 -11,16±7,19
0,022Q4 41,80±17,56
LNCaP and PC-3 percent of variation in apoptosis after stimulation with CM of adipocytes from periprostatic origin,
according to the obesity phenotype of patients. The % of difference in apoptotic cells between 50% and 0% CM was
calculated through the following formula: apoptotic cells (50% CM) – apoptotic cells (0% CM)*100 / apoptotic cells (0%
CM). Mean differencesSE are from experiments with CM from 6 patients (3 thin within Q1 of BMI and 3 obese in the
Q4 of BMI). Differences were computed by independent Student t tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI.
Early apoptosis refers to cells positive for Annexin-V but negative for IP, while in all apoptosis we consider all cells
positive for Annexin-V.
Experiment 3: Influence of conditioned medium in tumor cell (PC-3) invasion
We analyzed the invasive capacity of tumor cells after stimulation with SVF-derived CM
inside the insert, to evaluate the direct impact of SVF-produced molecules in tumor cells’
invasive behaviour, and inside the well, to ascertain the chemoattractant potential of SVF-
derived molecules for inducing tumor cells migration. We observed significant differences
in tumor cells stimulated with CM from visceral SVF inside the insert (Fig. 16). The tumor
cells invaded less when stimulated with visceral SVF CM independently of obesity
phenotype (all cases, p=0.0004; Q1 thin subjects, p=0.013; Q4 obese subjects, p=0.047). A
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trend towards a lower invasive potential was observed in periprostatic SVF-derived CM in
the well only on obese patients.
Fig.16: Invasive behaviour of tumor cells in the presence or absence of SVF-derived conditioned medium,
considering obesity profile. A) Visceral SVF-derived CM inside the insert, B) Periprostatic SVF-derived CM
inside the insert, C) Visceral SVF-derived CM in the well. D) Periprostatic SVF-derived CM in the well.
Differences among mean values were computed through independent Student t tests. Bars are representative
of the mean number of invasive cells, from experiments with CM from 6 patients (3 thin within Q1 of BMI
and 3 obese in the Q4 of BMI). Q1, quartile 1 of BMI; Q4, quartile 4 of BMI.
No significant differences in invasiveness of tumor cells were observed when we analyzed
results according to the localization of SVF-derived conditioned medium in the invasion
chamber (inside insert vs. in the well) and according to the patients obesity phenotype (Q1
vs. Q4 of BMI), in adipose tissue from periprostatic or visceral fat depots (Table 12).
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Table 12: Analysis of chemoattractive vs. direct migratory effect and obesity phenotype (BMI quartiles) in
tumor cells invasion phenotype
CM-associated invasiveness ratio (50% : 0% CM)
Chamber PP p* Vis p*
insert 0,86±0,15 0,58±0,06
well 0,88±0,45 0,109 0,81±0,13 0,109
Obesity
Q1 1,18±0,42 0,80±0,11
Q4 0,56±0,09 0,150 0,59±010 0,337
Invasive behaviour of tumor cells, considering the CM site in the invasive chamber and patient’s obesity profile.
Differences among mean valuesSE of CM-associated invasiveness ratio were computed through non-parametric Mann-
Whitney U tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI; PP, periprostatic adipose tissue; Vis, visceral adipose
tissue.
In Table 13 is represented the influence of the obesity profile the invasion, as well as the
anatomic region, considering the localization of the conditioned medium, but we didn’t
observe any significant difference.
Table13: Influence of the obesity profile and adipose tissue anatomic region conditioned medium in the
invasion of tumor cells.
CM-associated invasiveness ratio (50% : 0% CM)
Obesity insert p* well p*
Q1 0,82±0,14 1,16±1,42
Q4 0,62±0,10 0,200 0,53±0,09 0,150
Anatomic region
PP 0,86±0,15 0,88±0,45
Vis 0,58±0,06 0,200 0,81±013 0,262
Invasive behaviour of tumor cells, considering the obesity phenotype of patients and the origin of fat depots. Differences
among mean valuesSE of CM-associated invasiveness ratio were computed through non-parametric Mann-Whitney U
tests. Q1, quartile 1 of BMI; Q4, quartile 4 of BMI; PP, periprostatic adipose tissue; Vis, visceral adipose tissue.
DISCUSSION
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5. Discussion
During the last decades it has become evident that not only do cell-autonomous signals
regulate the behaviour of malignant cells, but also that heterotypic mechanisms can be
involved. Heterotypic mechanisms involve soluble secreted factors from cells that surround
tumors, extracellular-matrix components and interactions between stromal cells and tumor
cells, which create a specific and local peritumoral microenvironment. This process
involves constant bidirectional crosstalk between normal cells and partially or fully
transformated malignant cells (Hanahan & Weinberg, 2000).
The adipose tissue received little attention up to a few years ago, since it was viewed as a
merely energy-storing organ, relatively inert to its surrounding. Work by many different
laboratories over the course of the past few years has, in fact, shown that the adipose tissue
is a highly active endocrine organ that secretes numerous factors, including growth factors,
cytokines, hormone-like molecules and many other molecules (Ahima & Flier, 2000).
Several studies have demonstrated that the abundant number of growth factors and
cytokines released from adipose tissue can exert a substantial impact on the progression and
outcome of many human diseases, including prostate cancer (Baillargeon & Rose, 2006;
Housa et al., 2006; Ribeiro et al., 2006; Mistry et al., 2007). For instance, adipose tissue
surrounding prostate, i.e. periprostatic adipose tissue, is frequently invaded by prostate
tumor cells, although its contribution to the tumor microenvironment is largely unknown.
Only a recent study demonstrated that periprostatic adipose tissue produced locally IL-6 at
levels significantly higher than those in circulation (Finley et al., 2009).
Different fat depots contribute differently to disease and function. It has been appreciated
that fat tissue is regionally heterogeneous with respect to the content of stem cells and
metabolic function (Kirkland & Dax, 1984; Arner, 1997).
In the present study, we tried to reproduce in vitro, the interaction between adipose tissue-
produced molecules and castration-resistent and -sensible prostate tumor cells. Our purpose
was to find out the impact of periprostatic and visceral-derived molecules and its
subfractions (whole adipose tissue, adipocytes and stromal vascular fraction) in key
mechanisms, which are hallmarks of malignant phenotype in prostate cancer cells.
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The release of adipokines by adipose tissue has already been the subject of study in samples
from subcutaneous and visceral fat depots (Fain et al., 2004). It was demonstrated that in
vitro primary cultures of adipose tissue were a good model to reproduce specific
differences in endocrine function of fat from different anatomical locations (Boquest et al.,
2006; Thalmann et al., 2008). Thus, conditioned medium obtained after primary culture of
adipose tissue and its subfractions, may contain the adipokines usually produced in vivo
(Toda et al., 2009).
Our results showed that the conditioned medium of WAT cultures, derived both from
periprostatic and visceral origin, might promote proliferation of PCa castration-resistant
cells (PC-3) (WAT Vis p=0,056; WAT PP p=0,057). Visceral fat is associated with
systemic inflammatory activity (Fernandez-Real & Ricart, 2003), with lower differentiation
capacity of adipose stem cells (Toyoda et al., 2009) and with increased circulating levels of
pro-tumoral adipokines such as VEGF, bFGF, IGF, IL-6 (Mistry et al., 2007). Since
visceral fat metabolic activity seems to be more prone to favour tumor development and has
been associated with prostate cancer (Hsing et al., 2000; von Hafe et al., 2004), the
similarity of results between visceral- and periprostatic-induced growth of prostate cancer
cells, supports a role for periprostatic fat in prostate cancer growth. The local effect of pro-
inflammatory cytokines may be more relevant for periprostatic adipose tissue, which was
shown to produce significantly higher levels of IL-6 compared with circulating levels
(Finley et al., 2009).
Furthermore, examining whole-tissue production of proteins does not account for the
heterogeneous cellular components of adipose tissue. Results show a unique effect of WAT
in tumor cell growth, suggesting that the combined production of molecules from many cell
types within adipose tissue, may contribute differently to an expression pattern favourable
to castration-resistant tumor cells growth. In fact, interactive crosstalk between signalling
mechanisms have been described in adipose tissue (Toda et al., 2009).
Other studies that evaluated the influence of adipose tissue in cancer cells proliferation,
studied only subfractions and found that adipocyte secreted factors promote the growth of
PCa cells (Onuma et al., 2003; Tokuda et al., 2003) and other cancer cell types (Schnäbele
et al., 2009; Manabe et al., 2003; Amemori et al., 2007).
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For PCa castration-sensible cells (LNCaP), the conditioned medium from SVFs promoted
cell proliferation (SVF Vis p=0,002; SVF PP p=0,056). These results agree with others,
which demonstrated that stromal cells may support subcutaneous tumor growth when co-
injected with tumor cells (Zhu et al., 2006; Hall et al., 2007; Cavarretta et al., 2009). This
effect can be result of the transcriptome profile of adipose-derived adherent stromal cells, in
which genes involved in matrix proteins, growth factors and receptors and proteases were
shown to be highly transcribed (Katz et al., 2005; Peroni et al., 2008). However, caution
must be taken when analyzing these results, since it was observed that on in vitro culture,
transcripts associated with cell cycle quiescence, stemness and cytokines production were
down-regulated (Boquest et al., 2005).
When we analyze the proliferation considering the adipose tissue anatomic region of origin,
results demonstrate that LNCaP growth can be more influenced by SVF independently of
the origin of adipose tissue (in periprostatic adipose tissue SVF vs. WAT, p=0,003 and SVF
vs. adipocytes, p=0,043; in visceral adipose tissue SVF vs. WAT, p=0,003 and SVF vs.
adipocytes, p=0,011). In proliferation experiments we excluded the obesity factor, by using
conditioned medium from individuals with obesity profile within the normal quartile 2-3.
Future experiments should use conditioned medium from individuals with obesity profile
within Q1 vs. Q4 quartiles in order to elucidate the influence of the background obesity
phenotype in PCa tumor cell growth.
In apoptosis experiments we used conditioned medium from WAT and adipocytes cultures
to stimulate prostate tumor cells. Our results show no evidence of a significant role of
factors produced by adipose tissue from periprostatic or visceral origin in apoptosis of PC-3
and LNCaP cells. However, we found that in PCa castration-sensible cells, periprostatic
WAT-derived CM from obese patients induced apoptosis (p=0,029). Furthermore, in the
same cell line, periprostatic adipocytes-derived CM from obese individuals have a trend
toward a pro-apoptotic effect (p=0,080). Additionally, in castration-resistant cells, results
show that periprostatic adipocytes-derived CM from obese individuals also causes more
apoptosis (p=0,022).
Hoda & Popken (2008) observed that leptin, and adipocyte-derived adipokine, had anti-
apoptotic characteristics in castration resistant prostate cancer cell lines. Concordantly,
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others authors demonstrated similar results (Somasundar et al., 2004). However, these
studies used different methods for evaluating apoptosis and didn’t administer an apoptosis
inducer. One used the nucleosomal fragmentation assay (Somasundar et al., 2004), and the
other used an ELISA apoptosis assay (Hoda & Popken, 2008), which are methods that
analyze cell populations, while in our study a single cell approach was made through flow
cytometry quantification. Nevertheless, flow cytometry of adherent cells raise concerns
about the impact of trypsinization in cell apoptosis analysis.
These authors have stimulated the prostate tumor cells only with human recombinant leptin,
and a more complex interpretation arises from studying the impact of all adipokines
produced at the same time. A study on breast cancer cells stimulated with adipose tissue
derived-conditioned medium showed a synergistic role of adipokines in the induction of
anti-apoptotic transcriptional programs (Iyengar et al., 2003).
Sodium selenite induces cell death and apoptosis through the production of superoxide in
mitochondria and activation of the mitochondrial apoptotic pathway (Xiang et al., 2009). In
our apoptosis experiments, the cells were treated with sodium selenite. We hypothesize that
if the adipokines use an anti-apoptotic mechanism distinct from the mitochondrial pathway,
adipokine’s anti-apoptotic effect may not overcome apoptosis induced by selenite. Studies
using other methods to induce and measure apoptosis are needed to clarify if these results
are truly due to the adipose tissue-derived conditioned medium.
Prostate cancer cells have a striking tendency to metastasis (Van´t Veer & Weigelt, 2003;
Robinson et al., 2008), and this is the major cause of mortality for cancer patients. The
development of metastasis involves cellular transformation and growth, angiogenesis,
invasion of new organs and proliferation (Hanahan & Weinberg, 2000).
The adipose tissue stromal vascular fraction is known to produce several growth factors
with a relevant role in tumor cell migration and invasion, such as vascular endothelial
growth factor (VEGF), transforming growth factor beta 1 (TGFb1), basic fibroblast growth
factor (bFGF), plasminogen activator inhibitor -1 (PAI-1) (Festuccia et al., 1998; Sugamoto
et al., 2001; Qi et al., 2003; Ao et al., 2006).
The invasion study was made only in PC-3 cells, since they are more aggressive and
therefore more likely to invade. The experiment was done with stimulation by CM from
51
SVFs, since previous articles showed that adipose tissue-derived stromal cells migrate
towards the tumor and produce factors that have the potential to induce migration
(Cavarreta et al., 2009; Zhang et al.,2009). We tested two hypotheses: the first to evaluate
the direct influence of CM in PC-3, by adding CM inside the insert; and the second to
analyse the chemoattractive potential of molecules in CM, through using CM in the well.
Results show a suppression of PC-3 cells invasive potential when directly stimulated with
CM from visceral SVF cultures independently from patient’s BMI (all cases, p=0,0004; Q1,
p=0,01; Q4, p=0,05). These results contrast with published studies that report that
mesenchymal stem cells induce invasion in tumor cells (Yamada et al., 1999; Cavarreta et
al., 2009; Walter et al., 2009; Zhang et al.,2009). One possible explanation for these
contrasting results may be the short time of SVF culture used in our experiments, which
could no allowed a full potential production of growth factors. We cultured the SVF cells
until ~50% confluence (~48h), and then CM was removed after 48h, in a total culture time
of 4 days. Other reports using primary cultures of adipose tissue-derived stromal cells
harvested the CM after 6-14 days of culture (Rehman et al., 2004; Katz et al., 2005; Toyoda
et al., 2009).
The administration of CM in well to analyze chemoattraction yielded null results. This can
be due to lack of molecules produced by SVFs with capacity to attract tumor cells. For
instance, leptin, an adipokine exclusively expressed in adipocytes, seems to have a
significant role in monocyte and macrophages chemotaxis.  (Gruen et al., 2007). Further
studies are warranted using conditioned medium from WAT and adipocytes.
The adipose tissue is therefore an excellent candidate organ to play an important role in
influencing tumor behaviour through heterotypic signalling processes and may prove to be
critical for tumor survival, growth and metastasis of prostate cancer. This study adds to the
growing body of evidence that individual biological factors of the host (the medium in
which the tumor develops) plays an important part in disease development or progression.
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CONCLUSION AND FUTURE PRESPECTIVES
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6.Conclusion and future perspectives
In this study we observed that molecules produced in the adipose tissue influence
castration-resistant and -sensible prostate tumor cells’ proliferation, albeit each type of
tumor cell is influenced by different adipose tissue subfractions. Our results also
demonstrated that in obese individuals the factors produced by periprostatic adipose tissue
increase apoptosis of neoplasic cells, causing an unexpected pro-apoptotic effect.
Additionally, invasion assay experiments showed that the adipose tissue SVF subfraction,
suppresses invasion of PC-3 cells through a direct effect in tumor cells.
Future studies should address the following issues:
Increase the number of adipose tissue samples and replicate results from the present study;
Appreciate the activity of matrix metalloproteases in conditioned medium from all
subfractions and the expression of MMP2, MMP9 and MMP11 in tumor cells after
stimulation with CM from adipose tissue cultures (through luciferase reporter assays);
Evaluate adipocytes size from all samples of adipose tissue by microscopy and use the
information as an indirect metabolic phenotype to understand the differences encountered
in experiments;
Analyze gene expression of adipokines receptors in tumor cells when stimulated with
conditioned medium from adipose tissue culture;
Analyze gene expression of adipokines after stimulation of adipose tissue (WAT and
subfractions) with tumor cells-derived conditioned medium.
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